The revolutionary GLP-1 class of weight loss drugs are racking up blockbuster sales at a pace rarely seen in the pharmaceutical industry. But the pharma industry’s gain is the food industry’s loss. Read more...
Site référencé: Quartz
weight loss, morgan stanley, anti obesity medication, health medical pharma, glp 1 receptor agonists, ozempic, glucagon like peptide 1, peptide therapeutics, glp 1, smithfield foods, sc johnson, semaglutide, obesity, wegovy, novo nordisk, peptide hormones, anti diabetic drugs, shane smith, social issues, addiction
Quartz
Trump says China will 'open itself up to American business'
12/05/2025
Apple might be loading up some iPhone price hikes
12/05/2025
What recession ? Memorial Day travel is set to break records, AAA says
12/05/2025
The U.S. and China make a deal on trade. Here's what analysts are saying
12/05/2025
The U.S. and China called a trade war truce. Here's what to know
12/05/2025
Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study
12/05/2025
